CliffBio
small molecule

HORIZANT

GABAPENTIN ENACARBIL

Loss of exclusivityJune 2029latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameHORIZANT
Active ingredientGABAPENTIN ENACARBIL
Strength300MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2011
Marketing statusRX

Listed patents

PatentExpiresType
8795725June 2029product
8026279November 2026substance, product
8114909April 2026use U-1231

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

HORIZANT patent cliff — loss of exclusivity June 2029 | CliffBio